It is actually known that about 40–50% of CM cases harbor the mutation of the gene for v-Raf murine sarcoma viral oncogene homolog B (BRAF), leading to the BRAF protein constitutive activation, a serine/threonine-protein kinase in the MAPK signaling pathway [7]. The gene discussed is BRAF; the disease is cutaneous mastocytosis.